Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS

Neurotrophin treatment has so far failed to prolong the survival of individuals affected with amyotrophic lateral sclerosis (ALS), an incurable motoneuron degenerative disorder. Here we show that intracerebroventricular (i.c.v.) delivery of recombinant vascular endothelial growth factor (Vegf) in a SOD1G93A rat model of ALS delays onset of paralysis by 17 d, improves motor performance and prolongs survival by 22 d, representing the largest effects in animal models of ALS achieved by protein delivery. By protecting cervical motoneurons, i.c.v. delivery of Vegf is particularly effective in rats with the most severe form of ALS with forelimb onset. Vegf has direct neuroprotective effects on motoneurons in vivo, because neuronal expression of a transgene expressing the Vegf receptor prolongs the survival of SOD1G93A mice. On i.c.v. delivery, Vegf is anterogradely transported and preserves neuromuscular junctions in SOD1G93A rats. Our findings in preclinical rodent models of ALS may have implications for treatment of neurodegenerative disease in general.

[1]  W. Channing.  Never Too Late to Mend , 1859 .

[2]  W. H. Holden.  It is never too late to mend , 1930 .

[3]  P. Caroni,et al.  Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4 , 1994, The Journal of cell biology.

[4]  Rudolf Jaenisch,et al.  Mice lacking brain-derived neurotrophic factor develop with sensory deficits , 1994, Nature.

[5]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[6]  J. Belleroche,et al.  Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis , 1995, Journal of the Neurological Sciences.

[7]  A. Windebank.  Use of growth factors in the treatment of motor neuron diseases. , 1995, Advances in neurology.

[8]  F. L. Watson,et al.  Rapid Nuclear Responses to Target-Derived Neurotrophins Require Retrograde Transport of Ligand–Receptor Complex , 1999, The Journal of Neuroscience.

[9]  L. Powell-Braxton,et al.  IGF-I deficient mice show reduced peripheral nerve conduction velocities and decreased axonal diameters and respond to exogenous IGF-I treatment. , 1999, Journal of neurobiology.

[10]  D. Volles,et al.  Pharmacokinetic considerations. , 1999, Critical care clinics.

[11]  K. Koishi,et al.  Anterograde axonal transport of glial cell line-derived neurotrophic factor and its receptors in rat hypoglossal nerve , 2000, Neuroscience.

[12]  F. Condé,et al.  Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies , 2000, Neuroscience.

[13]  W. Frey,et al.  Delivery of Neurotrophic Factors to the Central Nervous System , 2001, Clinical pharmacokinetics.

[14]  Till Acker,et al.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.

[15]  Robert H. Brown,et al.  Rats Expressing Human Cytosolic Copper–Zinc Superoxide Dismutase Transgenes with Amyotrophic Lateral Sclerosis: Associated Mutations Develop Motor Neuron Disease , 2001, The Journal of Neuroscience.

[16]  W. Robberecht,et al.  Amyotrophic lateral sclerosis: pathogenesis. , 2000, Seminars in neurology.

[17]  J. O’Kusky,et al.  Mutant mouse models of insulin-like growth factor actions in the central nervous system , 2002, Neuropeptides.

[18]  C. Geis,et al.  Anterograde transport of tumor necrosis factor-alpha in the intact and injured rat sciatic nerve. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  J. Rothstein,et al.  Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Caroni,et al.  Accumulation of SOD1 Mutants in Postnatal Motoneurons Does Not Cause Motoneuron Pathology or Motoneuron Disease , 2002, The Journal of Neuroscience.

[21]  Mart Saarma,et al.  The GDNF family: Signalling, biological functions and therapeutic value , 2002, Nature Reviews Neuroscience.

[22]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[23]  Michael Sendtner,et al.  Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches , 2002, Nature Neuroscience.

[24]  C. Geis,et al.  Anterograde Transport of Tumor Necrosis Factor-α in the Intact and Injured Rat Sciatic Nerve , 2002, The Journal of Neuroscience.

[25]  B. Müller-Myhsok,et al.  Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. , 2002, American journal of human genetics.

[26]  R. Segal,et al.  Location, location, location: a spatial view of neurotrophin signal transduction , 2002, Trends in Neurosciences.

[27]  M. Azari,et al.  Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1G93A G1H mouse model of familial amyotrophic lateral sclerosis , 2003, Brain Research.

[28]  L. Austin,et al.  The effect of leukaemia inhibitory factor on SOD1 G93A murine amyotrophic lateral sclerosis. , 2003, Cytokine.

[29]  F. Gage,et al.  Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model , 2003, Science.

[30]  S. McMahon,et al.  Glial cell line‐derived neurotrophic factor increases calcitonin gene‐related peptide immunoreactivity in sensory and motoneurons in vivo , 2003, The European journal of neuroscience.

[31]  J. Rothstein.  Of mice and men: Reconciling preclinical ALS mouse studies and human clinical trials , 2003, Annals of neurology.

[32]  P. Carmeliet,et al.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.

[33]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[34]  M. Strupp.  Recent advances in amyotrophic lateral sclerosis research , 2004, Journal of Neurology.

[35]  P. Aebischer,et al.  ALS, IGF-1 and gene therapy: ‘it's never too late to mend’ , 2004, Gene Therapy.

[36]  Peter Carmeliet,et al.  VEGF: a critical player in neurodegeneration. , 2004, The Journal of clinical investigation.

[37]  P. Carmeliet,et al.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model , 2004, Nature.